Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 19/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | CTSD | P07339 | 1/20 | 0.57 |
| ▸ | CTSE | P14091 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1986191 | 1.00 | REN (1.00) | RENCYP3A4CTSDCTSE | |
| SCHEMBL4785745 | 1.00 | REN (1.00) | RENCYP3A4CTSDCTSE | |
| SCHEMBL1472318 | 1.00 | REN (1.00) | RENCYP3A4CTSDCTSE | |
| SCHEMBL30105796 | 1.00 | REN (1.00) | RENCYP3A4CTSDCTSE | |
| SCHEMBL4785747 | 1.00 | REN (1.00) | RENCYP3A4CTSDCTSE | |
| SCHEMBL1985127 | 0.90 | REN (0.81) | RENCYP3A4CTSDCTSE | |
| SCHEMBL5654200 | 0.88 | REN (0.79) | RENCYP3A4CTSDCTSE | |
| SCHEMBL5654202 | 0.88 | REN (0.79) | RENCYP3A4CTSDCTSE | |
| SCHEMBL5076941 | 0.88 | REN (1.00) | REN | |
| SCHEMBL5076945 | 0.88 | REN (1.00) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7915259-B2 | 7-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]phenyl}-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-(2,3-dimethylbenzyl)amide; retin inhibitor with other active ingredients; cardiovascular diseases and renal insufficiency | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-03-29 | — | — | US | disclosed |
| US-20080161313-A1 | Diazabicyclononene Derivatives and Use Thereof | ACTELION PHARMACEUTICALS LTD (CH) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161313-A1 | Diazabicyclononene Derivatives and Use Thereof | REN, ACE, AGTR1 | REN 1/4885CYP3A4 250/4885CTSD 903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.